Histone deacetylase inhibitors such as LBH589 (panobinostat) have shown promise as an antileukemic against MLL-rearranged infant ALL cells in vitro, with a promising therapeutic index and was effective at nanomolar concentrations [119]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.